Finance

Lists
Q3 2026 earnings • released • EPS beat +3.23% • Revenue miss -4.41%
See results
KURA:NASDAQ
Kura Oncology Inc
$7.77
+4.58%
(+0.34) 1D
Nov 13, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for KURA...
Open
$7.50
High
$7.82
Low
$7.30
Mkt. cap
713.90M
Avg. vol.
2.10M
Volume
2.23M
52-wk high
$13.90
52-wk low
$6.75
EPS
-$3.30
Beta
0.56
Shares outstanding
91.88M
No. of employees
260
Open
$7.50
High
$7.82
Low
$7.30
Mkt. cap
713.90M
Avg. vol.
2.10M
Volume
2.23M
52-wk high
$13.90
52-wk low
$6.75
EPS
-$3.30
Beta
0.56
Shares outstanding
91.88M
No. of employees
260
News stories
From web sources and news partners
About Kura Oncology Inc
CEO-
Employees260
Founded2014
HeadquartersSan Diego, California, United States
SectorHealth Care
IndustryBiotechnology
Websitekuraoncology.com
Analyst ratings
Based on 10 analysts giving stock ratings to KURA in the past 3 months
Strong buy
Buy
10
Hold
0
Sell
0
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for KURA in the last 3 months.
Highest
Current $7.77
$40.00 (+414.80%)
Average
$26.14 (+236.42%)
Lowest
$12.15 (+56.37%)
Analyst
Recommendation
Action
Price target
Projected
Date
Phil Nadeau
TD Cowen
Buy
Maintained
-
-
11/11/2026
Jason Zemansky
Bank of America Securities
Buy
Maintained
-
-
11/11/2026
Joseph Pantginis
H.C. Wainwright
Buy
Reiterated
$40.00
+414.8%
11/11/2026
Etzer Darout
Barclays
Buy
Maintained
$28.00
+260.4%
11/11/2026
Priyanka Grover
J.P. Morgan
Buy
Reiterated
$30.00
+286.1%
11/04/2026
David Nierengarten
Wedbush
Buy
Reiterated
$36.00
+363.3%
11/05/2026
David Dai
UBS
Buy
Maintained
$15.00
+93.1%
10/29/2026
Daniel Brims
Lake Street
Buy
Reiterated
$23.00
+196%
09/10/2026
Unknown Analyst
Leerink Partners
Buy
Maintained
$12.15
+56.4%
09/10/2026
Salim Syed
Mizuho Securities
Buy
Maintained
$25.00
+221.8%
08/31/2026
Charles Zhu
LifeSci Capital
Buy
Maintained
$28.00
+260.4%
08/13/2026
Robert Driscoll
Wedbush
Buy
Maintained
$36.00
+363.3%
07/28/2026
Unknown Analyst
Wedbush
Buy
Maintained
$36.00
+363.3%
07/28/2026
Unknown Analyst
Jefferies
Buy
Maintained
$28.00
+260.4%
06/15/2026
Unknown Analyst
Lake Street
Buy
Reiterated
$23.00
+196%
05/13/2026
Unknown Analyst
Guggenheim
Hold
Maintained
-
-
03/06/2026
Last report
Nov 10, 2026
Fiscal period
Q3 2026
-$0.78 / -$0.81
+3.23%beat
Revenue / Est. (USD)
22.84M / 23.89M
-4.41%miss
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
17.34M
18.26M
20.87M
22.84M
Cost of goods sold
64.46M
65.52M
62.13M
67.25M
Cost of revenue
64.46M
65.52M
62.13M
67.25M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
39.14M
31.56M
31.75M
30.25M
Operating expense
39.14M
31.56M
31.75M
30.25M
Total operating expenses
103.60M
97.08M
93.88M
97.50M
Operating income
-86.27M
-78.82M
-73.01M
-74.66M
Other non operating income
-
-
-
-
EBT including unusual items
-80.93M
-73.32M
-68.32M
-70.22M
EBT excluding unusual items
-89.42M
-73.32M
-68.32M
-100.80M
Income tax expense
71.00K
8.00K
5.00K
-
Effective tax rate
-0.09%
-0.01%
-0.01%
-
Other operating expenses
-
-
-
-
Net income
-81.00M
-73.33M
-68.33M
-70.22M
Net profit margin
-467.23%
-401.49%
-327.33%
-307.43%
Earnings per share
-0.92
-0.83
-0.77
-0.78
Interest and investment income
-
5.83M
5.03M
4.79M
Interest expense
-3.15M
-336.00K
-345.00K
-350.00K
Net interest expenses
-3.15M
5.49M
4.69M
4.44M
Depreciation and amortization charges
-
-
-
-
EBITDA
-85.86M
-78.46M
-72.64M
-74.33M
Gain or loss from assets sale
-
-
-
-30.59M
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps